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The innate immune system is the primary line of defense to protect the host from 
pathogen infection. Mammalian cells produce inflammatory cytokines and 
chemokines in response to innate immune signals and their expression is tightly 
regulated.  IFN-gamma Inducible Protein (IP-10), also known as C-X-C motif 
chemokine 10 (CXCL10), is an inflammatory chemokine belonging to the CXC 
chemokine family.  CXCL10 is chemotactic for many inflammatory cells, including 
macrophages, and altered expression of CXCL10 is associated with 
inflammatory diseases, including lupus nephritis and other autoimmune diseases. 
The Fli-1 transcription factor is a member of the Ets gene family and regulates 
the immune response, along with other cellular processes including its role in the 
pathogenesis of renal injury and systemic lupus erythematosus (SLE). Previous 
data has shown that Fli-1 heterozygous NZM2410 mice, a murine model of lupus 
with decreased Fli-1, had significantly decreased infiltration of inflammatory cells 
including macrophages in kidney. Similarly, in MRL/lpr lupus mice with 
decreased Fli-1, Decreased T cell infiltrates and CXCL10 levels in the kidney 
was founded. We hypothesize that Fli-1 is a critical regulator in directly 
modulating the expression of CXCL10. In this study, Fli-1 protein expression in 
endothelial cells transfected with Fli-1 specific siRNA was significantly decreased 
compared to the expression of Fli-1 in cells transfected with control siRNA.  
Additionally, endothelial cells transfected with Fli-1 specific siRNA produced 
significantly lower amounts of CXCL10 compared to cells transfected with control 




(LPS).  Chromatin immunoprecipitation (ChIP) assay was performed to show that 
Fli-1 binds Ets binding sites (GGAA/T) within the mouse CXCL10 promoter.  The 
human CXCL10 gene promoter was used to perform a transient transfection to 
determine that Fli-1 actively promotes transcription from the CXCL10 promoter. 
Mutation of the DNA binding domain of Fli-1 demonstrated that Fli-1 activates 
transcription of CXCL10 in both indirectly and directly ways, likely with the 
assistance of co-factors or post-transcriptional modifications. Together, the 
results indicate that Fli-1 is a novel, critical transcription factor in regulating the 
expression of the pro-inflammatory chemokine CXCL10 and provides a possible 
mechanism for the protective effect of decreased Fli-1 expression in lupus and 







Chapter 1 - Introduction 
Systemic Lupus Erythematosus  
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that is 
involved in inflammation in many different organs of the body, including the 
kidney, joints, skin, and brain causing symptoms that range from rashes, arthritis, 
heart disease vasculitis, serositis, and nephritis [1-3].  Approximately 90% of SLE 
patients are women aged 20-40 years and the occurrence of lupus is high in 
young African American women [1, 3]. The recent peak in mortality of SLE 
patients over the past 30 years has brought major concerns about the 
development of the disease and implementing new therapies to treat it. Among 
SLE patients, 50-70% of the mortality is due to lupus nephritis [1]. Lupus 
nephritis is a type of glomerulonephritis that is commonly seen in SLE patients. It 
is frequently associated with tubulointerstitial and/or vascular lesions in 
combination with impaired renal function, edema, proteinuria and hypertension 
[1]. The pathogenesis of lupus nephritis is poorly understood and much of what 
we know of the disease comes from animal models that exhibit lupus-like 
symptoms, including glomerulonephritis. Glomerulonephritis is initiated through 
renal deposition of immune complexes that consequently activates complement 
and Fc receptors [1]. In the late 1960’s, researchers discovered that patients 
with lupus nephritis contain autoantibodies against double stranded DNA [1]. 
With these antibodies acting against self, the kidney initiates the release of 




macrophages, dendritic cells, T cells and B cells into the glomerular and 
tubulointerstitial areas of the kidneys [4]. The infiltration of inflammatory cells, 
such as T helper type 1 (Th1) cells, initiates a cascade of events that contributes 
to the progressive deterioration of kidney structure and function.  
  Taking a closer look at the inflammatory cell types that infiltrate the kidney 
in lupus nephritis patients, T lymphocytes and B lymphocytes initiate the 
accumulation and infiltration of these cell types within the kidney [5]. T 
lymphocytes are composed of two classes, CD4 and CD8 cells, identified by their 
distinct surface markers. CD8 cells are cytotoxic T cells [5]; therefore they kill 
foreign pathogens on site, however CD4 T cells differentiate into effector 
subsets, the dominant ones being Th1 and Th2 cells [5]. Interleukin-12 (IL-12) 
drives the differentiation of naïve CD4 T cells to their Th1 cell subset [5]. Th1 
cells release chemokines, such as IFN-γ, to activate macrophages and recruit 
inflammatory mediators. Activation of monocytes causes them to mature into 
macrophages. Macrophages are antigen-presenting cells that induce 
phagocytosis of bacterial pathogens [5].  In addition to expressing IFN-γ, Th1 
cells can express TNF-α and TNF-β, which facilitate expression of adhesion 
molecules in blood vessels [6]. The release of these chemokines may cause 
local tissue damage. Th1 cells also release granulocyte macrophage colony-
stimulating factor (GM-CSF) that stimulates bone marrow stem cells to produce 
monocytes [5]. The release of IL-4 by CD4 lymphocytes leads to Th2 cell 
differentiation and, in turn, Th2 cells release a number of effector molecules 




extracellular parasites and play a role in asthma and allergies. Overall, Th1 cells 
initiate cell-mediated immunity and inflammation, while Th2 CD4 T lymphocytes 
regulate antibody-mediated immunity [5].  
  Dendritic cells (DCs) are equally involved in inflammation as 
macrophages, B-lymphocytes, and CD4 and CD8 cells and their subsets. DCs 
are derived from committed DC progenitors within the bone marrow and migrate 
to lymphoid and non-lymphoid tissue [8].  Between the two classes of DCs, 
conventional (cDC) and plasmacytoid (pDC), cDCs are antigen presenting and 
activate naïve T cells, and pDCs respond to viral and bacterial infections by 
producing large amounts of IFN-α and IFN-β [5]. 
  The pathogenesis of lupus nephritis is not fully understood. As mentioned 
previously, due to autoantibody production, complement and Fcγ receptors 
(FcγR) are activated and initiates the formation of immune complexes [1]. The 
activation of complement leads to glomerular injury which essentially leads to 
glomerulonephritis, similarly with FcγRs [1]. There are a number of nuclear 
antigens and autoantibodies implicated in the pathogenesis of lupus nephritis 
including: dsDNA, ssDNA, chromatin, histone, SSA, SSB, ribonucleoprotein and 
anti-C1q antibodies [1]. All of which have been found in the kidneys of LN 
patients.  How these anti-dsDNA and autoantibodies are deposited in the kidneys 
are not fully elucidated. There are a number of theories; however none have 
been proven or have any evidentiary support [1]. However, current studies are 





  Like many inflammatory diseases, cytokines and chemokines are closely 
involved in lupus nephritis development [1]. Inflammatory cells are all recruited by 
inflammatory cytokines, and all of these cell types contain a common chemokine 
receptor, CXCR3.  CXCR3 is a receptor for C-X-C motif chemokine 10 (CXCL10) 
the inflammatory chemokine this study is focused on. Detailed discussion 
regarding CXCL10 will be presented in another section.  
 
The Friend Leukemia Insertion Site 1 Transcription Factor 
The Ets gene family is composed of a number of transcription factors with 
a winged helix-turn-helix structure essential for protein-protein interaction and 
DNA binding [9]. Ets transcription factors are involved in various cellular 
processes, including the immune response, cellular proliferation, development, 
differentiation, transformation, and apoptosis [10]. All members of the Ets gene 
family contain an approximately 85 amino acid domain that binds to the 
conserved DNA binding motif (GGAA) [10]. One family member, the proto-
oncogene Friend Leukemia Insertion site 1 (Fli-1) transcription factor, regulates 
the immune response along with other cellular processes such as cell growth, 
proliferation, maturation, and survival [9].  Fli-1 recognizes the consensus DNA 
binding motif GGAA/T and, upon binding, can be either a positive or negative 
regulator of transcription [9].  
Several studies have implicated the Fli-1 transcription factor in SLE and 
lupus nephritis disease pathogenesis. The overexpression of the Fli-1 gene in 




within the kidneys, eventually leading to death due to tubulointerstitial nephritis 
and glomerulonephritis [11]. Because complete targeted disruption of the Fli-1 
gene has resulted in embryonic death within the animal models, researchers 
decided to investigate the reduced expression of Fli-1 on disease development in 
lupus disease [12]. MRL/lpr mice and NZM2410 mice are widely used murine 
models of lupus [13].   Fli-1 heterozygous (Fli-1+/-) congenic MRL/lpr mice with 
reduced expression of Fli-1 as well as Fli-1+/- congenic NZM2410 mice were 
generated by backcrossing with B6 Fli-1+/-mice. [11, 14].  As disease progressed, 
Fli-1+/-MRL/lpr mice and Fli-1+/- NZM2410 mice had significantly decreased serum 
levels of total IgG and anti-dsDNA antibodies compared to the Fli-1+/+ littermates 
[11].  Both in vivo and in vitro production of Monocyte Chemoattractant Protein-1 
(MCP-1) chemokine was significantly decreased in Fli-1+/- MRL/lpr mice and MS1 
cells where Fli-1 is knocked-down.  Also, the Fli-1+/- MRL/lpr mice and Fli-1+/- 
NZM2410 mice had markedly decreased proteinuria and pathologic renal scores.   
At 48 weeks of age, 100% of Fli-1+/- MRL/lpr mice were alive, in contrast to only 
27% of homozygous (Fli-1+/+ mice) littermates [11].  Notably, Fli-1+/- NZM2410 
mice with reduced expression of Fli-1 transcription factor had a marked reduction 
in nephritis, necrosis, and proteinuria compared to wild-type NZM2410 mice [14]. 
This is the same with the Fli-1+/- MRL/lpr mice.  Since infiltration of inflammatory 
cells into kidneys plays an important role in glomerulonephritis development, the 
inflammatory cells were quantitated and compared from Fli-1+/-NZM2410 mice 
and wild-type littermates.  In previous studies conducted in our lab, Fli-1+/-




were removed, and inflammatory cell infiltration analyzed. In previous studies 
we’ve seen a statistically significant decrease in all inflammatory cells including 
CD3+ T cells, CD19+ B cells, Ly-6B.2+ monocytes/macrophages and CD11b+ 
dendritic cells in the kidneys from Fli-1+/-NZM2410 mice compared to wild-type 
controls.  Ly-6B.2+ cells decreased 44%, and all other inflammatory cells 
decreased more than 50% in the kidneys from Fli-1+/- NZM2410 mice, as 
compared to wild-type controls.  Notably, there was a 70% decrease in CD19+ 
cells in Fli-1+/-NZM2410 mice versus wild-type controls [11].    
Because chemokines are known to play an important role in inflammatory 
cell infiltration, the expression of inflammatory cytokines and chemokines in 
kidneys from wild type and Fli-1+/-NZM2410 mice was also studied. The 
investigators observed significantly lower expressions of CCL5, MCP-1 and IL-6 
in kidneys from Fli-1+/-NZM2410 mice versus the kidneys of wild-type controls 
[14-16].  Both in vivo and in vitro production of MCP-1 was significantly 
decreased in Fli-1+/-MRL/lpr mice and Fli-1 knockdown MS1 cells and in the 
kidney. Furthermore, our lab has demonstrated that Fli-1 directly regulates 
expression of inflammatory cytokines including MCP-1, Regulated upon 
Activation, Normal T Expressed and Secreted (RANTES), and IL-6, all of which 
are associated with lupus nephritis [11, 14, 16-19].  
 
Inflammatory signaling in innate immunity and Inflammation:   
Innate immunity is an important part of the immune system in an 




[20]. The Toll-like receptor (TLR) was initially discovered in Drosophila, and later 
it was discovered that Drosophila [20].  The first human TLR was reported in 
1997, and now there are 10 functional Toll-like receptors in humans and 12 in 
mice [21].  TLRs are pattern recognition receptors (PRRs) that recognize 
pathogen associated molecular patterns (PAMPs) found on proteins, lipids, 
nucleic acids and lipoproteins, which are expressed on virus, bacteria, fungi and 
parasites [22].  Toll-like receptors have been identified in immune cells such as 
monocytes, dendritic cells, B cells and non-immune cells such as epithelial cells 
[22].  TLRs consist of an extracellular like receptor region, a transmembrane 
domain and a cytoplasmic Toll/IL-1 receptor domain [21].  Upon binding and 
activation by ligands, TLRs recruit a set of adaptor proteins such as Myeloid 
differentiation primary response protein 88 (MyD88) and TRIF-related adaptor 
molecule (TRAM), and then activate downstream kinases and transcription 
factors including Nuclear Factor-Kappa B (NF-kB), activator protein 1 (AP-1), 
Interferon regulatory factor 3 (IRF3) or IRF7 that regulate the expression of 
inflammatory cytokines and chemokines [23]. For example, the TLR-4 cascade 
can be MyD88 dependent, which in turn may lead to the stimulation of 
inflammatory cytokines, or MyD88 independent, which results in the expression 
of interferon inducible genes [24]. The Ets family is known to regulate 





Chemokine (C-X-C motif) ligand 10 and CXCR3 receptor 
Chemokines are a subfamily of cytokine-like molecules that induce chemotaxis 
and regulate functional properties of various leukocytes during inflammation [26]. 
The four groups of chemokines are distinguished by number and by the spacing 
of two conserved cysteine residues on the N-terminus (as shown in Figure 1). 
Two N-terminal cysteine residues, separated by a single variable amino acid, 
determine the CXC subgroup [27].The CXC subgroup is further divided into two 
subdivisions. The ERL positive motif, containing glutamine, arginine, and leucine 
near the N-terminal, and the ERL negative motif, which do not contain glutamine, 
arginine, and leucine near the N-terminal CXCL9, CXCL10, and CXCL11, are 
part of the ERL negative motif [26, 27]. All three CXC chemokines have a similar 
structure and share a ligand receptor, CXCR3 [28].  A G-protein coupled 
receptor, CXCR3 is expressed on many immunological cell types, such as 
activated T-cells, specifically Th1 CD4+ cells, as well as natural killer cells (NK) 
and CD8+ T cells. Increased recruitment of each of those cells to the site of 
infection can lead to chronic inflammation [4, 29-31]. The CXCR3 receptor is also 
expressed on myeloid dendritic cells, leukemic B-cells, and endothelial cells 
amongst other cell types [4].  
 As mentioned previously, chemokine (C-X-C motif) ligand 10 (CXCL10) is 
an interferon gamma inducible protein and may be referred to as IP-10 [32]. The 
human CXCL10 gene was initially found and identified as an early response 
gene in a monocyte-like cell line, U937 cells [26, 33]. The CXCL10 gene is 




which encodes a 98 amino acid protein and contains 4 exons, and a molecular 
mass of 10kDa, hence the name CXCL10 [26, 33].  The gene has been shown to 
regulate chemotactic and mitogenic activities associated with inflammation and 
cell proliferation. The human CXCL10 amino acid sequence has 63% homology 
with murine CXCL10 cDNA [33].  
 CXCL10 is expressed in a variety of cell types including monocytes, 
fibroblasts, neutrophils, keratinocytes, astrocytes, mesangial cells, and 
endothelial cells [26]. Functional characteristics of CXCL10 include its pleiotropic 
capabilities of inducing apoptosis, cell growth, and proliferation, as well as its role 
in inflammatory and infectious diseases and tumor growth. CXCL10 is a 
chemoattractant protein for monocytes, Th1 cells, DCs, and NK cells [4, 33, 34]. 
The expression of CXCL10 drives the recruitment of immune competent cells 
and the formation of lymphocyte infiltrates in autoimmune inflammation [26]. Th1 
cells, for example, are highly recruited by CXCL10 chemokine due to the high 
amount of IFN-γ that is being secreted by Th1 cells themselves. IFN-γ promotes 
the secretion of CXCL10 in various cell types, including Th1 cells. This, in turn, 
causes CXCL10 to recruit more Th1 cells, thus displaying a positive feedback 
loop [26, 35]. The recurring positive feedback loop leads to both the innate and 
adaptive immune response and, unfortunately, to the high inflammation that 






CXCL10 and Diseases 
 The manifestations of autoimmune diseases stem from effector 
mechanisms of the immune system that become directed towards self [5]. Given 
the role CXCL10 plays in the recruitment of inflammatory cells and the immune 
response, it is not surprising that the gene is implicated in the pathogenesis of 
various diseases. Studies have shown that CXCL10 is expressed in many Th1-
type inflammatory diseases including type 1 diabetes, psoriasis, multiple 
sclerosis, atherosclerosis, rheumatoid arthritis (RA), transplant rejection, and 
systemic lupus erythematosus (SLE) [26]. As mentioned previously, SLE is 
characterized by activation of T and B lymphocytes, autoantibody production, 
and the development of immune complexes resulting in damage to the tissue and 
organs [26]. Development of many autoimmune diseases can be contributed to 
abnormal T helper cell cytokine production, notably, CXCL10, which is especially 
relevant to SLE and the current study.  CD4+/CD8+ T cells that infiltrate the 
kidney express the CXCR3 receptor, which upon activation causes the 
production of CXCL10 [28-30]. When overproduced, CXCL10 leads to the 
recruitment of more Th1 inflammatory cells causing damage to the organs [34].  
Evidence linking CXCL10 and SLE has been provided in many recent studies 
[26].  In one study, researchers saw increased serum levels of CXCL10 in SLE 
patients [36]. After measuring CXCL10 levels and disease activity in SLE and RA 
patients they also measured MCP-1 levels as well, since MCP-1 is a known 
inflammatory chemokine and an early marker for other inflammatory diseases. 




RA and SLE.  However, researchers concluded that the elevated levels of MCP-1 
were generated from increased inflammation and were not necessarily 
dependent upon disease activity [36].  Alternately, the investigators concluded 
that CXCL10 serum levels increased in relation to severe disease activity after 
measuring anti-DNA antibodies [36].  Those findings suggest that CXCL10 is an 
indicator of SLE activity [36]. In recent plasma chemokine studies, researchers 
observed increased levels of CXCL10 produced by peripheral blood 
mononuclear cells (PBMC) from SLE patients [37]. The objective was to 
determine whether there was chemotactic preference for Th1 chemokines or Th2 
chemokines or both in SLE patients. Elevated levels of CXCL10, detected from 
the PBMCs, were significantly higher in SLE patients versus healthy patients 
[37].  Other evidence linking CXCL10 and SLE are the increased levels of 
CXCL10 seen in the cerebrospinal fluid of SLE patients. The exact role of 
CXCL10 within the pathogenesis of SLE has yet to be identified [38].  Previous 
reports demonstrated that NF-kB (nuclear factor kappa-light-chain-enhancer of 
activated B cells) transcription factor is involved in regulating expression of 
CXCL10 [39].    
   
Fli-1, SLE, and CXCL10 
CXCL10 is a major macrophage and T-cell chemotactic cytokine, and our 
lab observed significantly reduced macrophage and T-cell infiltration into the 
kidney from Fli-1+/- NZM2410 mice with reduced expression of Fli-1 compared to 




kidney CXCL10 concentrations from Fli-1+/- MRL/lpr mice were significantly lower 
compared to these from wild-type MRL/lpr controls [28]. There were significantly 
fewer T cells in the kidney, significantly reduced T cells expressing CXCR3, and 
decreased CXCR3 expression in the kidneys, all of which supports Fli-1’s role in 
regulating CXCL10-CXCR3 recruitment of T cells to the kidney. Taking all 
information into account, this suggests that Fli-1 transcriptionally controls the 
expression of CXCL10.  In addition, we have preliminary data demonstrating that 
endothelial cells transfected with specific Fli-1 siRNA had markedly reduced 
expression of Fli-1 protein and produced significantly decreased amounts of 
CXCL10 after stimulation with TLR4 ligand, lipopolysaccharide (LPS), compared 
with endothelial cells transfected with control siRNA.  Analyzing the promoter 
region of CXCL10 revealed there are many potential Ets DNA-binding sites in the 
CXCL10 promoter. This leads us to our hypothesis that Fli-1 is a critical 
regulator in directly modulating the expression of CXCL10, which is 
associated with inflammation in autoimmune diseases and other 
inflammatory disease development. The below study was designed to test this 
hypothesis by determining if Fli-1 regulates the expression of CXCL10 and 




Chapter 2 – Hypothesis 
 
Fli-1 is a critical regulator in directly modulating the expression of CXCL10, 
which is associated with inflammation in autoimmune diseases and other 
inflammatory disease development. 
 
Specific Aims 
Specific Aim 1: To confirm that Fli-1 regulates the expression of CXCL10. 
Specific Aim 2: To investigate the mechanism(s) of how Fli-1 regulates 





Chapter 3 – Materials and Methods 
 
Cells 
Endothelial cells (EC) are a cell type of choice for multiple reasons. As 
mentioned previously ECs contain the CXCR3 receptor and it also expresses 
CXCL10 [4]. Previous studies have demonstrated that  Fli-1  is highly expressed 
in ECs [40].  MS1 cells, a murine pancreatic islet endothelial cell line, were 
purchased from the American Type Culture Collection (ATCC, Manassas, VA) 
and maintained with DMEM containing 5% fetal bovine serum (FBS). Human 
Umbilical Vein Endothelial cells (HUVECs) were purchased from Lonza (Basal, 
Switzerland) and maintained in EBM-2 Basal Medium supplemented with EGM-2 
SingleQuot Kit growth factors.  NIH3T3 cells were purchased from ATCC and 
maintained with DMEM with 10% fetal bovine serum and 1% 
penicillin/streptomycin. All cells were grown at 37°C in 5% CO2. 
 
siRNA Transfections 
MS1 cells and HUVECs were cultured to confluence in sterile T-75 Falcon culture 
flask with complete growth media. To remove cells from the flasks, they were 
treated with 0.05% Trypsin (MS1) or TrypLE (HUVECs) and incubated at room 
temperature for 1-2 minutes until cells came off the plate. Both MS1 cells and 
HUVECs were neutralized with growth media and counted using a 
hemocytometer. Once plated in a 6-well plate at 0.5 x 105 cells/well with each 




hours in preparation for transfection. After the 24hr incubation, the media was 
removed from the cells, replaced with fresh media, and placed back into the 
incubator for one hour to equilibrate. An RNAi duplex was prepared by combining 
5nmol Stealth Silencer Human Fli-1 siRNA (Ambion, Walthan, MA) oligo with 
Opti-MEM medium (Thermo Fisher Scientific, Waltham, MA) for Fli-1 transfection 
and siRNA Negative Control, Med GC (Thermo Fisher Scientific) and Opti-MEM 
medium for the control. An RNAi Max solution was prepared containing 25pmol 
of lipofectamine as the transfection reagent and combined with Opti-MEM 
medium. Two solutions of RNAi Max were prepared for the Fli-1 transfection and 
the control, respectively. The RNAi Max and the RNAi duplex were combined, 
equal amounts of the mixture were added to the control only 6-well plate and the 
Fli-1 only 6-well plate. The plates incubated overnight. 
  
Lipopolysaccharide (LPS) Stimulation  
LPS was used to activate the TLR signaling pathway in cells to observe CXCL10 
production. The cells were cultured in a T-75 flask to 80% confluence and plated 
onto a 6-well plate at a concentration of 1 x 105 cells/well, each well containing 2 
ml of media and incubated at 37C, 5% CO2 for 24hrs. The media was changed 
the next day.  Cells were stimulated with TLR4 ligand, lipopolysaccharide (LPS) 
to induce CXCL10 production.  Cells were stimulated with 1g/mL of LPS, and 
samples were collected at the 0, 2, 6 and 24-hour time points. A dosage 




being administered to the cells. We stimulated the cells with 0.25g/ml, 0.5g/ml, 
1g/ml, 5g/ml, and 10g/ml of LPS. The supernatants were collected at 2 hours, 
6 hours and 24 hours after stimulation and stored at -80C.   
 
Immunoblot Analysis 
Immunoblots were performed to monitor the efficiency of siRNA knockdown.  
Cells were collected in 1X Phosphate Buffer Saline (PBS) and lysed with 
Radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl, pH 7.5; 150 mM 
NaCl; 1% Triton X-100; 0.5 % deoxycholate; 0.1 mM EGTA; 1.0 mM EDTA; 0.1% 
SDS and protease inhibitor mixture). Equal amounts of each sample were loaded 
and ran on a 12% Tris Glycine SDS-PAGE gel (Novex, Life Technologies) under 
reducing conditions. The proteins were transferred onto a polyvinylidene 
difluoride membrane and blocked for 1 hour in Odyssey Blocking Buffer (LI-COR, 
Lincoln, Nebraska). The membrane was later probed with 1:100 dilution of 
specific rabbit polyclonal Ab against Fli-1 and 1:200 dilution of β-actin Rabbit 
mAb (Cell Signaling Technology). After three washes with PBS containing 0.1% 
Tween 20 (PBST), the membrane was incubated with donkey anti-rabbit IgG 
secondary antibody (LI-COR)). Chemiluminescence signals were captured using 
an Odyssey chemilminescence and infrared imager (LI-COR).  The expression 





Enzyme-linked Immunosorbent Assay 
A 96-well polystyrene microplate was coated with antihuman CXCL10 capture 
antibody and incubated overnight at room temperature. After 2-3 washes, the 
plate was blocked with reagent diluent (1% bovine serum albumin in PBS), and 
samples were added after a second wash. Recombinant human CXCL10 
standards were added following a seven point standard curve starting at 
2000pg/ml with a 2-fold serial dilution. Standards and samples were sealed and 
incubated at 4C overnight. Plates were aspirated, washed, and separately 
probed with biotinylated goat anti-human CXCL10 detection antibody, 
streptavidin-HRP, and finally, color substrate solutions, H2O2 and 
Tetramethylbenzidine. Washes were conducted between each step. To stop the 
reaction, the plate was coated with an acid solution, 2N H2SO4. CXL10 levels 
were measured using a microplate reader at a wavelength of 450nm.  
 
IP-10/CXCL10 Primers for ChIP Assay 
To design the primers for CXCL10, we obtained the 5’ UTR from the murine 
CXCL10 sequence using the Ensembl genome database (www.ensembl.com, 
gene number ENSMUSG00000034855) and identified the promoter region. Next, 
the sequence was uploaded into the Genomatix MatInspector program to identify 
potential ETS transcription factor binding sites within the promoter region of 
CXCL10.    Once those sites were identified through the MatInspector program, 




the sequence. With this information, we proceeded to design appropriate primers 
for the promoter region of CXCL10. According to Thermofisher Scientific, the 
most ideal primers should be low in GC count, with an appropriate length of 15 – 
20 nucleotides, melting temperatures around 60C, and similar TM’s for each 
primer pair along with other stipulations.  An oligonucleotide calculator 
(http://biotools.nubic.northwestern.edu/OligoCalc.html) was used to ensure these 




A Chromatin Immunoprecipitation (ChIP) Assay was performed to determine if 
Fli-1 directly binds to the promoter region of CXCL10 using the EpiTect ChIP 
OneDay kit from QIAGEN. Approximately 2-4 million cells were cultured in 
preparation for the ChIP Assay. Cells were fixed with fresh fixing buffer (1% 
Formaldehyde in 1X PBS) and washed with 1X PBS before harvesting with cell 
harvesting buffer containing protease inhibitor cocktail (PIC) in 1X PBS. Cells 
were then lysed and sonicated to obtain ChIP-ready chromatin. ChIP chromatin 
was isolated via immunoprecipitation where the anti-Fli-1 rabbit polyclonal 
antibody was used. A normal rabbit IgG antibody was used for a negative control 
and the complete IP Fraction as the positive control.  DNA elution buffer and 
ChIP-Grade Proteinase K were added to the ChIP chromatin IP fraction to isolate 
the targeted DNA fraction. DNA purification was performed through a series of 





Real Time qPCR 
Real Time qPCR was used to quantitate our ChIP assay results and was 
performed in triplicate.  We used our ChIP fraction DNA samples and the primers 
that were designed for the CXCL10 promoter. The experiment was performed 
following the basic steps of denaturation, annealing, and extension. Primers, 
DNA, Water, and Bio-Rad SybrGreen Supermix (contains polymerase, dNTPs, 
MgCl2, and dyes) was combined and loaded onto the PCR plate and amplified 
using a thermocycler. For the control, we used MCP-1 primer. These controls 
have been published in previous papers by our lab [15, 16, 25]. Once the primers 
detect the promoter region following IP with anti-Fli-1 antibodies, the RT-pCR 
machine puts out critical threshold values. Our data is quantitated based on 
these critical threshold (CT) measurements.. CT values are defined as changes in 
fluorescence per PCR cycle number at the set base threshold. To normalize our 
input, specific antibody was compared to the % input value for each 
immunoprecipitation represented as CT (% Input CT – (specific antibody CT – 
Dilution Factor). Genomic DNA was calculated and represented as CT (% Input 
CT – Fli-1 specific antibody CT). CT (genomic input) and CT (specific antibody) 
are the mean threshold cycles of PCR performed. Fold Enrichment (2CT) was 




Reporter & Expression Constructs 
Primers were designed specifically for the promoter region of CXCL10, using the 
previously mentioned technique. To clone the full length CXCL10 promoter 
region, -2069bp upstream of the transcription start site, we used the ChIP 1 
reverse primer (5' CAC TTG GGT TCA TGG TG 3') and ChIP 14 forward primer 
(5' GAA TTC GGA GGT CTA CCT 3') that were designed previously for the ChIP 
Assay. These two primers along with restriction enzymes Kpn1 and Sma1 
(underlined) were used to obtain the entire 2069bp promoter region through 
cloning.  Genomic DNA isolated from a B6 mouse was amplified using 
polymerase chain reaction (PCR). DNA concentration was measured after 
isolation. Although were able to isolate and clone the murine CXCL10 promoter, 
we were able to obtain the human CXCL10 promoter already sequenced and 
inserted into the pGL4 vector. The CXCL10 human promoter was used for our 
DNA transfections. It was obtained from Dr. David Proud (University of Calgary, 
Alberta, Canada) and initially generated from human genomic DNA [41]. The 
972bp promoter construct corresponds to the human CXCL10 gene and its 
promoter sequence ranges from -875 to +97 in relation to the transcription start 
site [41].  In comparing, both, the murine and human CXCL10 promoter 
construct, we found 63% homology within the two sequences. This percentage 
was calculated based on neighbor joining tree method using ClustalX2.1 
program. Taking this information in account, we opted to use the human CXCL10 
promoter construct for the DNA transfections.  
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 The following expression constructs were used in the transient 
transfection assays. The murine Fli-1 expression construct, containing a 5’ kozak 
sequence and a flag tag, was provided to our laboratory by Dr. Dennis Watson 
(Medical University of South Carolina) [42]. The Fli-1 expression construct was 
cloned in the pCDNA3.0 vector (Life Technologies), which is under regulation of 
the CMV (Human cytomegalovirus) promoter. DNA transfections were also 
performed using the human Fli-1 gene cloned into the pSG5 expression 
vector (AgilentTechnologies, Santa Clara, CA) and a Fli-1 DNA-binding 
mutant construct inserted into the pSG5 vector. This mutation contains a 
single amino acid change of tryptophan 321 to arginine preventing DNA 
binding, which was provided to our laboratory by Dr. Maria Trojanowska 
(Boston University School of Medicine Arthritis Center, Boston, MA) [42]. 
 
DNA Transfections 
The NIH3T3 cell line, also known as murine embryonic fibroblast cells, contain no 
endogenous Fli-1 and are a commonly used cell line for DNA transfection. 
NIH3T3 cells were seeded in a 6 well plate at a concentration of 4x105 cells/well 
and incubated at 37C, 5% CO2 overnight in preparation for the transfection. 
Cells were transfected using Fugene 6 (Promega) as the transfection reagent 
and 0.1g of the pGL4/human CXCL10 reporter construct. The Fli-1 expression 
vector was transfected into the cells in increasing doses (0.025g, 0.05g, 0.1g, 
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0.2g, 0.25g, 0.5g and 1g) and empty expression constructs (pcDNA or 
pSG5) was also added so that equal amounts of total DNA were transfected into 
the cells. A Renilla luciferase construct (pRL/TK) was also transfected into the 
cells to normalize for transfection efficiency. After transfection, the cells were 
incubated at 37C, 5% CO2 for 48 hours. To harvest the cells, they were washed 
with sterile 1X phosphate buffer saline and then collected in passive lysis buffer 
in preparation for the next experiment, the luciferase assay.  
 
Luciferase Assay 
Using the Dual-Luciferase Reporter Assay System (Promega) and the 
Luminoskan Ascent Microplate Luminometer (Thermo Fisher Scientific, Waltham, 
MA), we measured luciferase activity within our NIH3T3 cells. Briefly, 20μl of the 
cell lysate was placed into white walled wells of a 96-well plate. Using the 
luminometer, one hundred microliters of the provided Luciferase Assay Reagent 
II was added to the lysate, a brief waiting period observed and then the luciferase 
value recorded. Next, 100 μl of Stop and Glo Reagent was added to the samples, 
a brief waiting period observed and the Renilla luciferase value recorded. We 
normalized transcription activity to our Renilla luciferase construct pRL/TK 
(Promega), which was co-transfected into our cells. Fold activation was 
calculated by dividing normalized luciferase activity over pGL3 basic and 





To determine significance within the data, an unpaired, two-tailed Student’s t-test 
based on equal or unequal variances was conducted between two groups in the 
DNA transfection experiments.  P values less than 0.05 or 0.01 were determined 
as statistically significant. Significant differences in CXCL10 production were 
determined via analysis of standard curve with Prism software from GraphPad 
(San Diego, CA) and two-tailed Student t-test (Microsoft Excel), which were 




Chapter 4 – Results 
 
 
Specific Aim 1- To confirm that Fli-1 regulates the expression of CXCL10 
 
Inhibiting expression of Fli-1 leads to significantly decreased production of 
CXCL10 
CXCL10 is a chemoattractant for inflammatory cells and reduced expression of 
Fli-1 resulted in decreased inflammatory cell infiltration in kidneys in murine 
model of lupus (see Table 1) [19].  We have found that endothelial cells in 
glomeruli express high amounts of Fli-1 protein [40].  Given that CXCL10 
expression was decreased in Fli-1(+/-) MRL/lpr mice [28], we first chose to 
determine if inhibiting expression of Fli-1 affects production of CXCL10 in 
endothelial cells.  Both the murine endothelial cell line, MS1, and primary human 
endothelial cells, HUVECs, were transfected with Fli-1 specific siRNA and 
negative control siRNA, as described in the Methods section.  The cells lysates 
were collected with RIPA buffer and an immunoblot was performed to measure 
the Fli-1 protein.   As shown in Figure 2 and Figure 3, the expression of Fli-1 
protein was inhibited after transfection with Fli-1 specific siRNA compared to the 
cells transfected with control siRNA. To determine the appropriate concentration 
of LPS to use on endothelial cells, a dosage response assay was performed on 
untransfected cells. Figure 4 shows that increasing the dosage of LPS to murine 
endothelial cells increases the amount of CXCL10 up until 1g/ml. At this point, 
the amount of CXCL10 decreases. Based on these results we chose to treat the 
cells in future experiments with 1g/ml LPS. 
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 To determine if the expression of Fli-1 affects production of CXCL10 in 
endothelial cells, MS1 endothelial cells were transfected with Fli-1 specific siRNA 
and control siRNA, and stimulated with 1 g/ml of LPS to induce an inflammatory 
response.  The supernatants were collected at 0, 6 and 24 hours after stimulation 
and the concentration of the CXCL10 protein measured by ELISA. As shown in 
Figure 5, the production of CXCL10 in MS1 cells transfected with specific Fli-1 
siRNA was significantly reduced compared to the cells transfected with control 
siRNA at 6 hours and 24 hours after stimulation (mean SD, 141.8  61.42 pg/ml  
versus 146.19  80.28 pg/ml before stimulation – 0 hours, 
and 645.7  167.1 pg/ml versus 336.2  93.26 pg/ml at 6 hours after LPS 
stimulation, P value = 0.009967; and 1493.75  392.35 pg/ml versus 540.01 
 187.37 pg/ml at 24 hours after LPS stimulation, P value = 0.004096) (P < 0.05 
for each comparison; n = 2 (6 replicates per group). Decreased amounts of 
CXCL10 in the cells transfected with specific Fli-1 represented more than a 50% 
reduction compared to the cells transfected with negative control siRNA.  
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Figure 2. Expression of Fli-1 was inhibited in murine endothelial cells with 
specific Fli-1 siRNA transfection  
Murine endothelial cells were treated with 20nmol Stealth silencer mouse Fli-1 
siRNA or siRNA negative control. The cells were collected 24 hours later and 
lysed with RIPA buffer.  Fli-1 was detected by an immunoblot. The Fli-1 protein 
was indicated at 51kDa in MS1 endothelial cells. Beta actin (42kDa) was used as 





Figure 3. Expression of Fli-1 was inhibited in human umbilical vein 
endothelial cells with transfected specific Fli-1 siRNA 
Human umbilical vein endothelial (HUVEC) cells were treated with 5nmol stealth 
silencer human Fli-1 siRNA or siRNA negative control.  The cells were collected 
24 hours later and lysed with RIPA buffer.  Fli-1 was detected by an immunoblot.  
Fli-1 protein was detected at 51kDa in HUVECs. Beta actin (42kDa) was used as 


















Figure 4.  CXCL10 was produced in MS1 cells following LPS stimulation in 
a dose-dependent way.  MS1 cells were stimulated with 0.25g/ml, 0.5g/ml, 
1g/ml, 5g/ml, and 10g/ml of LPS and supernatants were collected 6 hours 
and 24 hours after stimulation.  CXCL10 concentrations were measured via 
sandwich ELISA. Experiment was performed in triplicate and values are shown 






Figure 5. Inhibiting expression of Fli-1 leads to significantly decreased 
production of CXCL10  
Murine endothelial cells were transfected with specific Fli-1 siRNA or control 
negative siRNA respectively and simulated with 1g/mL LPS.  The supernatants 
were collected at 6 and 24 hours following the stimulation. CXCL10 
concentrations were determined by a sandwich ELISA.  The experiment was 
performed in triplicate and values are shown as means SD of N=2 experiments 
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Specific Aim 2 – To determine the mechanism(s) of how Fli-1 regulates the 
expression of CXCL10 
 
Fli-1 binds to the CXCL10 promoter in endothelial cells 
Next, we investigated how Fli-1 regulates the expression of CXCL10. Fli-1 is 
known to bind the consensus ETS DNA binding motif GGAA/T and in previous 
studies the Fli-1 transcription factor has been proven to regulate many 
inflammatory cytokines and chemokines by directly binding to their promoter 
regions [25] [15].  Using Genomatrix Matlnspector software, the potential Fli-1 
ETS binding sites in the promoter region of CXCL10 were examined. After 
thorough examination, 46 putative Fli-1 binding sites were identified as shown in 
Figure 6. Fourteen primer pairs were designed to cover all 46 Fli-1 binding sites 
(Table 2).  ChIP Assay was performed using specific anti-Fli-1 antibody to 
determine if Fli-1 binds to the promoter of CXCL10 as described the methods.  
We determined PCR products from ChIP 3, ChIP 4, ChIP 7, and ChIP 8 were 
significantly enriched for the Fli-1 antibody compared to normal IgG control (p 
values less than 0.01) (Figure 7).  
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Figure 6. Putative ETS/Fli-1 binding to sites on the mouse CXCL10 
promoter.  
Forty-six putative binding sites were identified on the mouse genomic DNA 
promoter of CXCL10 using Genomatrix MatInspector. The number above the 
dash represents the number of potential ETS binding sites within each ChIP 





Table 2. ChIP Primers 
The 5’ UTR from the murine CXCL10 sequence was obtained and used to 
identify the promoter region of the mouse CXCL10 genome.  Primers pairs were 









Figure 7. Fli-1 binds to the CXCL10 promoter.  
MS1 endothelial cells were cross-linked with formaldehyde, chromatin was 
isolated from the cells and immunoprecipitated with specific Fli-1 or control IgG 
antibodies. The genomic fragments associated with the immunoprecipitated DNA 
were amplified by PCR using the primers designed in Table 2.  Fold changes (Fli-
1 antibody/control IgG) were calculated by RT-PCR and are shown for each 
primer pair. Data presented are shown as the mean ± standard deviation where a 
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Fli-1 drives the transcription of CXCL10  
 
 DNA transfection assays were performed to determine whether Fli-1 
regulates the expression of CXCL10. Using the human CXCL10 promoter, we 
amplified it using PCR and genomic DNA and cloned the promoter into the pGL3 
basic reporter construct.  To determine if Fli-1 drives the expression of CXCL10 
we transfected increasing dosages of Fli-1 into NIH3T3 embryonic fibroblast 
cells, which contain no endogenous Fli-1. Looking at the luciferase data in 
Figure 8, the results demonstrate that as the dosage of Fli-1 increases so does 
CXCL10 expression within the promoter.
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Figure 8. Fli-1 drives activation of CXCL10.  
NIH3T3 cells were transfected with murine Fli-1 expression construct and the 
human pGL4/CXCL10 reporter construct using the FuGene 6 transfection 
reagent. Increasing amounts of the Fli-1 expression construct (0.025g, 0.05g, 
0.1g, 0.25g, 0.5g, and 1g) were transfected into NIH3T3 cells. Values are 
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Mutation of DNA-binding domain of Fli-1 partially impairs transcriptional 
activation of the CXCL10 promoter  
To determine whether Fli-1 is driving transcription of CXCL10 directly or 
indirectly, we performed another DNA transfection using a Fli-1 binding mutant. 
The Fli-1 binding mutant contains a mutation to prevent DNA binding to the 
promoter region. This mutation consists of a single amino acid change from 
tryptophan 321 to arginine (W to R) [42]. Figure 9 shows that mutating Fli-1 





Figure 9. Fli-1 regulates CXCL10 through indirect binding of the promoter and 
with the help of unknown cofactors. NIH3T3 cells were transfected with human 
Fli-1 expression construct and pGL4/CXCL10 reporter construct using the 
FuGene 6 transfection reagent. 1g of human Fli-1 expression construct and 1g 
of human Fli-1 binding mutant were transfected into NIH3T3 cells. Values are the 
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Chapter 5 – Discussion 
 
 The innate immune system is our primary line of defense to protect the 
host from infection from pathogens [22]. Mammalian cells produce inflammatory 
cytokines and chemokines in response to innate immune signals and their 
expression is tightly regulated [20, 22].  IFN-gamma Inducible Protein (IP-10), 
also known as CXCL10, is an inflammatory chemokine belonging to the CXC 
chemokine family [26].  CXCL10 is chemotactic for many inflammatory cells 
including macrophages and dendritic cells [26]. Altered expression of CXCL10 is 
associated with inflammatory diseases, including lupus nephritis and other 
autoimmune diseases; its association with numerous autoimmune diseases is 
what drives interest in determining regulatory factors for this inflammatory 
cytokine [26]. The Fli-1 transcription factor, a member of the Ets gene family, is 
known to regulate numerous cellular processes, the immune response being one 
of interest [10]. Fli-1 has also been associated with the pathogenesis of renal 
injury and SLE, which has been studied in our lab. Previous studies have shown 
that Fli-1 heterozygous (Fli-1+/-) NZM2410 mice, with reduced expression of the 
Fli-1 transcription factor, had a marked reduction in nephritis, necrosis, and 
proteinuria compared to wild-type NZM2410 mice [19]. The Fli-1+/- NZM2410 
mice, also had reduced infiltration of inflammatory cells including macrophages, 
T cells, B cells, and neutrophils in kidneys and survived significantly longer 
compared with wild-type NZM2410 controls [19].   Our lab has demonstrated that 
Fli-1 directly regulates expression of inflammatory chemokines and cytokines 
including MCP-1, RANTES, and IL-6, all of which are associated with 
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inflammatory diseases [15, 16, 25]. Because Fli-1+/- NZM2410 had significantly 
decreased infiltration of inflammatory cells, including dendritic cells and 
macrophages, and IP-10/CXCL10 is known to attract these cells, our hypothesis 
was that Fli-1 is a critical regulator in directly modulating the expression of 
CXCL10.  Within this study we initially looked at mouse endothelial cells. As 
mentioned previously,  the overexpression of Fli-1 has been implicated in SLE 
development and is also found in endothelial cells [16, 19, 43]. After LPS 
stimulation within these cells, we saw an increase in CXCL10 production over 24 
hour time period (Figure 5). With the siRNA knockdown of Fli-1 within the same 
cell type we see significant reduction of CXCL10 6 and 24 hours after LPS 
stimulation. Similar results have been seen within the G-SCF study where it was 
determine that Fli-1 was a direct regulator (Lennard Richard et al., unpublished 
data). In comparing the current data with previous studies we can conclude from 
this experiment that the partial absence of Fli-1 leads to reduced CXCL10 
expression. These results are consistent with our initial observation and first aim 
that Fli-1 plays a role in regulation CXCL10.  
 Looking into the mechanism behind the relationship of Fli-1 and CXCL10 
we determined that Fli-1 binds to the promoter region of CXCL10 at several 
different sites based on results from the ChIP Assay (Fig. 7). We have identified 
that Fli-1 binds to 6 regions within the murine promoter identified by ChIP assay 
(ChIP3 [-1830 to -1660], ChIP4 [-1677 to -1501], ChIP7 [-1200 to -1027], ChIP8 
[-1027 to -858], ChIP9 [-873 to -733], and ChIP10 [-753 to -602]) (Figure 7). 
Since ChIP 3 and ChIP 4, ChIP 7 and ChIP 8, and ChIP 9 and ChIP 10 sites are 
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very close to each other we will need to conduct further analysis within the 
CXCL10 promoter to identify which sites Fli-1 actually bind to. Some proposed 
methods of determining specific sites Fli-1 may bind to would be to insert a 
mutation. A mutation will hopefully hinder the binding of Fli-1 and we can narrow 
down the exact location where Fli-1 is binding within the promoter region.  
 Upon performing the transient DNA transfection, using human Fli-1 
expression construct, luciferase assay results determined Fli-1 drives CXCL10 
activation starting from 0.025g of Fli-1 to 0.1g of Fli-1 (Fig. 8). These results 
clearly show that Fli-1, not only plays a role in the regulation of CXCL10 but 
through binding of the promoter region.. Based on our data from DNA transient 
transfection of the human Fli-1 binding mutant, the mechanism Fli-1 uses to 
regulate the expression of CXCL10 may be both direct and indirect ways. 
Mutation of Fli-1’s DNA binding domain, shown in Figure 9, shows an 18% 
reduction of transcriptional activity. This is reduction is significant when 
compared to the human Fli-1 expression construct (P = 0.00213). Since the 
reduction is rather low, these results suggest that Fli-1 maybe driving 
transcription largely indirectly and there may be other factors assisting with the 
transcription of CXCL10. These results are very similar to previously published 
literature looking at Fli-1 regulation of MCP-1 [44]. Our lab provided evidence that 
Fli-1 regulated MCP-1 both directly and indirectly due to fact that Fli-1 was 
binding to the promoter MCP-1 and driving transcription in a dose-dependent 
manner [44]; however when the DNA binding mutant was introduced 
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transcriptional activity was reduced by only 27%, which led researchers to 
conclude that Fli-1 regulated MCP-1 largely indirectly [44].  
 Although we were able to provide viable evidence of Fli-1’s role in 
CXCL10 expression there are a few more areas that we would like to explore 
with this project. The majority of our work was conducted in pancreatic murine 
endothelial cells and or fibroblast cells for our DNA transfections; and although 
these cells were sufficient enough to use for our current work, our goal is to 
transition to murine and/or human kidney cells in hopes to obtain similar results 
and gain a greater insight on Fli-1’s role with CXCL10. This would greatly mimic 
realistic views on the mechanism that is taking place and introduce more 
authentic environmental factors that may be assisting Fli-1 in transcription. 
 In drawing conclusions from this study, Fli-1 has been identified as a 
critical regulator of IP-10/CXCL10 in endothelial cells. While Fli-1 binds to the 
CXCL10 promoter, the mechanism of activation is mainly through indirect binding 
and interactions with the promoter.  These findings differ from our original 
hypothesis of Fli-1 being a direct regulator of CXCL10; however the Fli-1 
transcription factor is still a critical regulator. This can be seen through results 
from our first aim, siRNA knockdown of Fli-1 results in a significant reduction in 
CXCL10 protein expression, and previous studies where Fli-1 is a major 
regulator of other inflammatory cytokines and chemokines [15, 16, 25, 44]. There 
are a number of factors that maybe assisting Fli-1 with the transcriptional 
regulation of CXCL10, these include post-translational modifications and 
transcriptional co-activators. Our upcoming goals are to identify the co-factors 
 
 49 
and post-transcriptional modifications that may be involved through use of 
proteomics, specifically the MALDI-TOF mass spectrometer and other molecular 
biology techniques.   Many cytokines such as IFN-α and IFN-β are known to 
stimulate other cytokine production; we also plan to determine if Fli-1 regulates 
expression of CXCL10 following stimulation with IFN- and IFN-.  The primary 
goal of this project was to establish a relationship between Fli-1 transcription 
factor and CXCL10 due to the fact of there being evidence of Fli-1 being a major 
chemokine regulator and CXCL10 playing a role in inflammation in autoimmune 
diseases. Our studies will add more to the list of chemokines that Fli-1 regulates 
and contribute to further studies of the transcription factor. Lupus nephritis is the 
leading cause of death in SLE patients today and our current studies will 
contribute to the molecular and immunological understanding of the disease.  
CXCL10 is associated with several other inflammatory diseases and role of Fli-1 
in these diseases are needed to be explored.  
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